A firm that specializes in initial-public-offering research and money management made some major moves in the third quarter. Renaissance Capital LLC bought more Palantir...
Deals and Financings Suzhou MediLink Therapeutics out-licensed global rights (ex-China) for its antibody-drug conjugate candidate against Human Epidermal Growth Factor Receptor 3 (HER3) to...